// App-Quantinova.ai

6003 : Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients with N0-N2a squamous cell carcinoma of the head and neck (SCCHN): Results of the GORTEC 2007-01 phase III randomized trial.

Researchers

Presenter

  • Jean Bourhis

Principal Investigators

  • xu Shan Sun

  • Christian Sire

  • Yungan Tao

  • Laurent Martin

  • Cedric Khoury

  • Philippe Maingon

  • Etienne Bardet

  • Michel Lapeyre

  • Thierry Chatellier

  • Nathalie Ollivier

  • Alexandre Cornely

  • Anne Auperin

Medical Centers

  • Lausanne University Medical Center, , Lausanne,, Switzerland

  • Besancon Hospital, Besancon, France

  • CH de Bretagne Sud, Lorient, France

  • Institut Gustave-Roussy, Villejuif, France

  • Centre Guillaume Le Conquerant, Le Havre, France

  • Center Georges-Francois Leclerc, Dijon, France

  • Georges-Francois Leclerc Center, Radiotherapy Department, Dijon, France

  • ICO Rene Gauducheau, Nantes, France

  • Centre Jean Perrin, Clermont-Ferrand, France

  • Clinique Mutualiste, Saint Nazaire, France

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • France

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Oropharyngeal carcinoma

  • Solid malignancies

Biomarkers

  • Serpin B3

Drug/Treatment

  • Carboplatin

  • Erbitux

Outcome

  • Positive

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT00609284

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved